News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
NovaVive offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency.
Data from a study conducted by Gluck Equine Research Center (UKY) and Rood & Riddle Equine Hospital has demonstrated efficacy of Settle® to treat endometrial cups in mares. No other treatment has been found effective to date.
A paper has been published in the Australian Veterinary Journal, “The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle”, summarizing a research study conducted by CSIRO.
In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.
NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.
An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.